Product Images Haloperidol

This is a table showing the adverse reactions occurring in 21% of patients treated with oral haloperidol in double-blind, parallel placebo-controlled clinical trials. The table lists the percentage of patients who experienced gastrointestinal disorders such as constipation, dry mouth, and salivary hypersecretion, as well as nervous system disorders including extrapyramidal disorder, hyperkinesia, tremor, hypertonia, dystonia, bradykinesia, and somnolence. The table also notes that the total reporting rate for extrapyramidal disorder includes individual symptoms and events that did not meet the threshold of >1% for inclusion in the table.*

Elderly patients with dementia-related psychosis may be at greater risk of death if treated with antipsychotic drugs, according to a study of 17 placebo-controlled trials. The risk of death in drug-treated patients was 1.6 to 1.7 times the risk of placebo-treated patients, with cardiovascular and infectious causes being most common. While observational studies show that this increased mortality may also apply to conventional antipsychotic drugs, it is unclear whether the increased mortality is caused by the drugs or characteristics of the patients. Haloperidol Injection, USP is not approved for treating these patients.*

The text describes a product with two versions, one with a strength of 5mg per ml and another with a strength of 50mg per 10ml. The product is sold in different unit sizes, one with a unit of 25 1mL fillings/vials and the other with a 2mL vial. The packaging is individually wrapped and each version has a unique NDC code.*

Not available.*

Haloperidol is a medication available in injection form that should only be administered intramuscularly. Each milliliter of the injection contains 5 milligrams of the drug. It is important to store the injection in a sterile environment and protect it from light. The drug is packaged in a single dose vial, which should be used only once.*